mTOR: a potential therapeutic target in osteoarthritis?

Related Experiment Video

Updated: Apr 17, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

15.0K

Bandna Pal1, Helal Endisha1, Yue Zhang1

  • 1Division of Genetics and Development, The Toronto Western Research Institute, Toronto Western Hospital, The University Health Network (UHN), 60 Leonard Avenue, Toronto, ON M5T 2S8 Canada.

Drugs in R&D
|February 18, 2015
PubMed

Insights

Mammalian target of rapamycin (mTOR) is implicated in osteoarthritis (OA) pathogenesis. Inhibiting mTOR in preclinical models reduced OA severity, suggesting its therapeutic potential for this degenerative joint disease.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Rheumatology

Background:

  • Osteoarthritis (OA) is a degenerative joint disease marked by cartilage loss, bone remodeling, and inflammation.
  • Mammalian target of rapamycin (mTOR) regulates cell growth, proliferation, and protein synthesis.
  • Emerging evidence links mTOR to cartilage development, homeostasis, and OA-related degeneration.

Purpose of the Study:

  • To review the role of mTOR in cartilage development and homeostasis.
  • To explore the potential of mTOR as a therapeutic target for osteoarthritis.

Main Methods:

  • Literature review of studies investigating mTOR in cartilage biology and OA.
  • Analysis of preclinical data on mTOR inhibition in OA mouse models.

Main Results:

  • mTOR signaling is crucial for normal cartilage development and homeostasis.
  • Pharmacological and genetic inhibition of mTOR has demonstrated efficacy in reducing OA severity in mouse models.
  • These findings highlight mTOR's involvement in the pathological processes of OA.

Conclusions:

  • mTOR plays a significant role in maintaining articular cartilage health.
  • Targeting mTOR presents a promising therapeutic strategy for managing osteoarthritis.
  • Further research is warranted to translate these findings into clinical applications.

More Related Videos

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

3.0K
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles05:50

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles

Published on: June 2, 2023

2.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
14.2K